Business Wire

Electric Motor Manufacturer YASA Secures £15m Growth Funding, Opens New Oxford Production Facility

Del

YASA, the world’s leading manufacturer of axial-flux electric motors and controllers, today announced raising £15 million in growth funding. Universal Partners joins Parkwalk Advisors and other existing investors in the round, bringing the total raised by the company to £35 million.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180131005889/en/

An axial-flux electric motor manufactured by YASA (Photo: Business Wire)

An axial-flux electric motor manufactured by YASA (Photo: Business Wire)

This £15 million investment follows YASA’s signing of long-term development and supply agreements with customers in the automotive sector. The company has recently opened a new 100,000-unit capacity production facility in Oxford, UK to meet the growing demand for its products. Eighty per cent of YASA’s production is destined for export to automotive manufacturers across the world, including China.

The new production facility will be officially opened today by the Secretary of State for Business, Energy and Industrial Strategy, the Rt Hon Greg Clark MP. A range of YASA-powered vehicles will be on display at the event, including cars from Nissan, Jaguar Land Rover and Williams Advanced Engineering.

The Business Secretary Greg Clark MP said, “YASA is a brilliant example of what can be achieved when government, academia and industry come together to turn the best ideas from the best minds into scale-up companies.”

YASA’s innovative axial-flux electric motor design offers best-in-class power and torque densities and is ideally suited to both hybrid and pure electric vehicle applications. With YASA’s technology, automotive manufacturers have greater design flexibility to improve vehicle performance whilst reducing vehicle weight.

YASA motors and controllers enable automotive manufacturers to meet increasingly stringent emissions targets whilst delivering exciting driving experiences. In addition to automotive, YASA motors are used in marine applications and in aerospace where high power density and torque density are critical.

Dr. Chris Harris, YASA’s CEO said, “Our customers are looking to adopt innovative new technologies such as YASA’s axial-flux electric motors and controllers in order to meet the needs of the rapidly expanding hybrid and pure electric automotive market. This additional £15 million in growth funding will enable YASA to further invest in the volume production capacity necessary to meet our customers’ requirements, and to address markets beyond automotive including aerospace and marine.”

Andrew Birrell of Universal Partners - who joins YASA’s board - said, “YASA has unique and highly differentiated axial-flux motor technology that offers clear advantages in terms of power and torque density compared to their competition in class. We are pleased to have the opportunity to invest and are very excited by the prospects for the Company.”

Alastair Kilgour, Chief Investment Officer at Parkwalk Advisors said, “YASA has made excellent commercial progress over the past two years and we are pleased to continue to support the Company in this latest financing round. With the rapid growth of electrification in automotive and other sectors such as aerospace and marine, we believe YASA has huge business potential.”

<ends>

EDITOR’S NOTES

YASA http://www.yasa.com/

YASA is the world’s leading manufacturer of axial-flux electric motors and controllers for automotive, aerospace and marine applications. YASA’s proprietary electric motor and controller products offer the smallest, lightest form factor for a given power and torque requirement. The privately-held company is based in Oxford, the UK’s automotive manufacturing heartland. Investors include Parkwalk Advisors and Universal Partners.

Contact information

For all media enquiries, contact:
Tamara Sword
TRM&C
tamara@trmandc.co.uk
+44 (0)7906 638351

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 10:49Pressemelding

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha